MYOKARDIA
MyoKardia is a clinical-stage biopharmaceutical company that engages in discovering, developing, and commercializing targeted therapies for the treatment of rare cardiovascular diseases. The company's focus is on the treatment of heritable cardiomyopathies and genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. It utilizes its medicine platform to generate an initial pipeline of therapeutic programs for the chronic treatment of the two most common forms of heritable cardiomyopathy-hypertrophic cardiomyopathy and dilated cardiomyopathy. The company was founded in 2012 and is headquartered in Brisbane, California.
MYOKARDIA
Industry:
Biopharma Biotechnology Health Care Medical Therapeutics
Founded:
2012-09-01
Address:
Brisbane, California, United States
Country:
United States
Website Url:
http://www.myokardia.com
Total Employee:
251+
Status:
Closed
Contact:
650 741 0900
Email Addresses:
[email protected]
Total Funding:
98 M USD
Technology used in webpage:
SPF Amazon IPv6 Google Apps For Business Microsoft Azure DNS YouTube Google Amazon Virginia Region Pound Sterling Japanese Yen
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
BridgeBio Pharma
BridgeBio Pharma investment in Series B - MyoKardia
Cowen Group
Cowen Group investment in Series B - MyoKardia
Casdin Capital
Casdin Capital investment in Series B - MyoKardia
Cormorant Asset Management
Cormorant Asset Management investment in Series B - MyoKardia
Perceptive Life Sciences
Perceptive Life Sciences investment in Series B - MyoKardia
Cormorant Asset Management
Cormorant Asset Management investment in Venture Round - MyoKardia
Cowen Group
Cowen Group investment in Venture Round - MyoKardia
Sanofi
Sanofi investment in Venture Round - MyoKardia
Casdin Capital
Casdin Capital investment in Venture Round - MyoKardia
BridgeBio Pharma
BridgeBio Pharma investment in Venture Round - MyoKardia
Official Site Inspections
http://www.myokardia.com
- Host name: 165.89.235.72
- IP address: 165.89.235.72
- Location: Trenton United States
- Latitude: 40.2187
- Longitude: -74.7404
- Metro Code: 504
- Timezone: America/New_York
- Postal: 08629
More informations about "MyoKardia"
Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash
Oct 5, 2020 · NEW YORK & BRISBANE, Calif.-- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) and MyoKardia, Inc. (Nasdaq: MYOK) today announced a definitive merger …See details»
MyoKardia - Crunchbase Company Profile & Funding
MyoKardia is a clinical-stage biopharmaceutical company that develops targeted therapies for the treatment of rare cardiovascular diseases. View contacts for MyoKardia to access new leads and connect with decision-makers.See details»
BMS to buy MyoKardia for access to late-stage heart …
Oct 6, 2020 · In a purchase designed to boost its cardiovascular disease drug portfolio, Bristol Myers Squibb will pay $13.1 billion in cash for MyoKardia. The centerpiece of the deal is mavacamten, a treatment for a type of chronic heart …See details»
MyoKardia - Org Chart, Teams, Culture & Jobs - The Org
View MyoKardia's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Bristol Myers Squibb Completes Acquisition of MyoKardia, …
Nov 17, 2020 · Through the transaction with MyoKardia, Bristol Myers Squibb gains mavacamten, a potential first-in-class cardiovascular medicine for the treatment of obstructive hypertrophic …See details»
MyoKardia - LinkedIn
MyoKardia | 14,729 followers on LinkedIn. Driven by the heart | We officially combined with Bristol Myers Squibb to further strengthen our scientific capabilities and treatments for...See details»
Bristol-Myers Squibb to buy heart treatment maker for …
Oct 5, 2020 · Bristol-Myers Squibb is acquiring the Californian drugmaker MyoKardia for $13.1bn to expand its portfolio of cardiovascular drugs. The New York-based pharmaceutical company said it had agreed to...See details»
Bristol-Myers Squibb to Acquire MyoKardia for $13.1B, Expanding ...
Oct 5, 2020 · Bristol-Myers Squibb (BMS) has agreed to acquire MyoKardia for $13.1 billion cash, the companies said today, in a deal designed to expand the buyer’s cardiovascular drug …See details»
Bristol Myers Squibb to Acquire MyoKardia - s21.q4cdn.com
A copy of the tender offer statement and the solicitation/recommendation statement will be made available to all stockholders of MyoKardia free of charge at www.myokardia.com or by …See details»
Bristol Myers Squibb acquires MyoKardia, expanding …
Mar 1, 2021 · Founded in 2012 and based in Brisbane (California), MyoKardia is a clinical-stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the …See details»
Bristol Myers Squibb acquires MyoKardia Inc., a …
Nov 17, 2020 · MyoKardia’s proprietary drug discovery platform brings together advances from the fields of cardiovascular genomics and heart muscle biology which enables its scientists to target certain heart diseases at the genetic level.See details»
Anatomy of a deal: How MyoKardia got BMS to bump up its …
Oct 21, 2020 · On Sept. 2, Bristol Myers CEO Giovanni Caforio , M.D., called MyoKardia CEO Tassos Gianakakos with an offer to buy all outstanding shares of MyoKardia at $185 apiece, in …See details»
Bristol Myers expands heart drug business with $13 billion deal for ...
Oct 5, 2020 · (Reuters) - Bristol Myers Squibb Co said on Monday it would buy MyoKardia Inc for about $13 billion to bolster its portfolio of heart disease treatments, ahead of the potential loss …See details»
Bristol Myers to buy MyoKardia in $13B bet on targeted drugs for …
Oct 5, 2020 · Bristol Myers Squibb on Monday said it will pay $13.1 billion to acquire MyoKardia, a developer of medicines for genetic forms of heart disease. Bristol Myers is paying $225 per …See details»
Bristol Myers Squibb Completes Acquisition of MyoKardia, …
Nov 17, 2020 · Through the transaction with MyoKardia, Bristol Myers Squibb gains mavacamten, a potential first-in-class cardiovascular medicine for the treatment of obstructive hypertrophic …See details»
MyoKardia: The Precision Cardiac Medicine Company with
Jul 7, 2020 · At least that’s the mantra at the heart of MyoKardia, a California-based biotech company that is developing precision medicine for cardiovascular diseases (CVDs). “We want …See details»
FDA approves first cardiac myosin inhibitor - Nature
May 10, 2022 · Bristol Myers Squibb has secured FDA approval for mavacamten, for obstructive hypertrophic cardiomyopathy (obstructive HCM). The company gained the first-in-class cardiac …See details»
Myosin inhibitor flexes, myosin activator flops - Nature
Nov 3, 2020 · Drug developers have long been working on small-molecule modulators of cardiac myosin, a protein that controls heart muscle contractions, for cardiovascular applications. In …See details»
Bristol Myers Squibb Completes Acquisition of MyoKardia
Nov 17, 2020 · Through the transaction with MyoKardia, Bristol Myers Squibb gains mavacamten, a potential first-in-class cardiovascular medicine for the treatment of obstructive hypertrophic …See details»